Related articles

• Randomized Controlled Trial

  Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

  Cancer. 2002 Jun 1;94(11):3032-41.

• Randomized Controlled Trial

  Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

  Cancer. 2003 May 1;97(9):2290-300.

• Randomized Controlled Trial

  The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised,...

  Eur. J. Cancer. 2004 Feb 1;40(3):403-10.

Show more related articles...